{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:09:50Z","timestamp":1788948590422,"version":"build-2803163510"},"reference-count":15,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Two immunocompromised patients with relapsing babesiosis were cured using a well-tolerated course of tafenoquine (171 and 212 days, respectively), with negative polymerase chain reactivity intentionally exceeding the 120-day lifespan of erythrocytes before discontinuing the tafenoquine. During the first 10 days of tafenoquine both patients also received an atovaquone-containing drug regimen. This was prescribed based on the demonstrated benefit of atovaquone on the efficacy of tafenoquine for completely eradicating B. microti in an animal study.<\/jats:p>","DOI":"10.3390\/pathogens15090960","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:24:02Z","timestamp":1788945842000},"page":"960","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Two-Phase Approach to the Use of Tafenoquine Was Associated with Cure of Babesiosis in Two Immunocompromised Patients with Relapsing Babesiosis"],"prefix":"10.3390","volume":"15","author":[{"given":"Nonso","family":"Osakwe","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Northern Westchester Hospital-Northwell Health, Mount Kisco, NY 10549, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary P.","family":"Wormser","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, New York Medical College, Valhalla, NY 10595, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"115008","DOI":"10.1016\/j.diagmicrobio.2020.115008","article-title":"Frequency and magnitude of seroreactivity to Babesia microti in 245 patients diagnosed by PCR in New York State","volume":"97","author":"Wormser","year":"2020","journal-title":"Diag. Microbiol. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/cid\/ciae238","article-title":"Tafenoquine for relapsing babesiosis: A case series","volume":"79","author":"Krause","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/cid\/ciac473","article-title":"Broad antimicrobial resistance in a case of relapsing babesiosis successfully treated with Tafenoquine","volume":"76","author":"Rogers","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"102211","DOI":"10.1016\/j.tmaid.2021.102211","article-title":"Long-term safety of the tafenoquine antimalarial chemoprophylaxis regimen: A 12-month, randomized, double-blind, placebo-controlled trial","volume":"45","author":"Martidis","year":"2022","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.diagmicrobio.2016.02.016","article-title":"Persistence of babesiosis for >2 years in a patient on rituximab for rheumatoid arthritis","volume":"85","author":"Raffalli","year":"2016","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Thiagarajan, P., Parker, C.J., and Prchal, J.T. (2021). How do red blood cells die?. Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.655393"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/infdis\/jiz119","article-title":"Could the drug Tafenoquine revolutionize treatment of Babesia microti Infection?","volume":"220","author":"Mordue","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e0020421","DOI":"10.1128\/AAC.00204-21","article-title":"Tafenoquine Is a promising drug candidate for the treatment of babesiosis","volume":"65","author":"Liu","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Prasad, P.J., and Wormser, G.P. (2022). Failure of an approximately six week course of Tafenoquine to completely eradicate Babesia microti Infection in an immunocompromised patient. Pathogens, 11.","DOI":"10.3390\/pathogens11091051"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/infdis\/jiad315","article-title":"Tafenoquine-Atovaquone combination achieves radical cure and confers sterile immunity in experimental models of human babesiosis","volume":"229","author":"Vydyam","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13071-020-04235-7","article-title":"Activities of artesunate-based combinations and tafenoquine against Babesia bovis in vitro and Babesia microti in vivo","volume":"13","author":"Carvalho","year":"2020","journal-title":"Parasit. Vectors"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJMoa1612165","article-title":"Post-babesiosis warm autoimmune hemolytic anemia","volume":"376","author":"Woolley","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/trf.17252","article-title":"Warm autoimmune hemolytic anemia with anti-Jka specificity following babesiosis masquerading as a delayed hemolytic transfusion reaction","volume":"63","author":"Jacobs","year":"2023","journal-title":"Transfusion"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.14740\/jh820","article-title":"Autoimmune Hemolytic Anemia Associated with Human Babesiosis","volume":"10","author":"Rajapakse","year":"2021","journal-title":"J. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bjh.18710","article-title":"Autoimmune haemolytic anaemia secondary to babesiosis: A review of reported cases and description of a novel association with cold antibody-mediated haemolytic anaemia","volume":"201","author":"Jacobs","year":"2023","journal-title":"Br. J. Haematol."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/9\/960\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:48:31Z","timestamp":1788947311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/9\/960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":15,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["pathogens15090960"],"URL":"https:\/\/doi.org\/10.3390\/pathogens15090960","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}